Clinical characteristics

No. of patients

ARID2

CDKN2A

KRAS

NF1

RB1

TP53

Mut

χ²

p

Mut

χ²

p

Mut

χ²

p

Mut

χ²

p

Mut

χ²

p

Mut

χ²

p

Total

262

Sex

Male

169

10

0.439

0.508

8

0.068

0.795

6

0.000

1.000

8

1.566

0.211

8

2.416

0.120

55

5.192

0.023^#

Female

93

3

3

3

8

9

18

Age

<60

134

7

0.040

0.842

4

0.157

0.692

4

0.005

0.944

8

0.009

0.925

13

4.666

0.031^#

49

10.340

0.001^#

≥60

128

6

6

5

8

4

24

Race

Asian

156

11

3.570

0.059^#

11

6.147

0.013^#

3

1.650

0.199

9

0.077

0.782

13

2.163

0.141

62

27.080

<0.001^#

non-Asian

106

2

0

6

7

4

11

Pathological typing

HCC

225

13

2.020

0.338

9

1.130

0.685

5

7.027

0.028^#

11

6.138

0.038^#

16

5.632

0.047^#

69

8.015

0.012^#

ICC

34

0

2

4

4

0

3

cHCC-ICC

3

0

0

0

1

1

1

Primary site

Liver

228

13

1.010

0.315

9

0.004

0.947

5

5.541

0.019^#

12

0.417

0.151

17

1.621

0.203

70

7.046

0.008^#

Intrahepatic bile duct

34

0

2

4

4

0

3

Treatment type

Pharmaceutical therapy, NOS

132

7

0.066

0.798

4

0.903

0.342

5

0.000

1.000

8

0.001

0.975

8

0.080

0.777

42

2.071

0.150

Radiation therapy, NOS

130

6

7

4

8

9

31

T stage

T1 - T2

183

10

0.068

0.795

9

0.301

0.584

5

0.338

0.561

12

0.033

0.855

10

1.049

0.306

51

0.000

0.997

T3 - T4

79

3

2

4

4

7

22

M stage

M0

248

13

0.061

0.805

10

0.000

1.000

7

2.363

0.124

15

0.000

1.000

16

0.000

1.000

68

0.135

0.713

M1

14

0

1

2

1

1

5

N stage

N0

252

13

0.000

1.000

10

0.017

0.897

8

0.077

0.782

16

0.022

0.882

17

0.038

0.846

71

0.042

0.837

N1

10

0

1

1

0

0

2

Stage

I - II

177

10

0.190

0.663

9

0.494

0.482

5

0.177

0.674

12

0.431

0.512

10

0.633

0.426

50

0.040

0.841

III - IV

85

3

2

4

4

7

23